An interventional study of Cleerly Labs and Cleerly ISCHEMIA in Coronary Artery Disease, sponsored by Cleerly, Inc.. Active, not recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Cleerly, Inc. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.
Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 105th largest by planned enrollment of the 745 interventional ones that give a count, is one of 36 that started in 2024, is one of 352 with no phase, reaches primary completion later than 39 of the 141 other live ones, and was the 1,050th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:
EBI Anti Sepsis BV · Sites in United States, Belgium, Netherlands and 1 more country
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 55+
Mayo Clinic · Sites in United States
Ages 40+
Eli Lilly and Company · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Australia, Germany and 2 more countries
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 104 · Phase 3 112 · Phase 4 141
First in 1985; this study’s year is marked. 36 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 107 across the 745 interventional studies, 186 across the 357 observational. Of the 840 that completed or were terminated, 355 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
378 of 1,104 have an industry lead sponsor. The 10 most frequent:
Cleerly, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Cleerly, Inc. has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
51 of the studies in Coronary Artery Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT06713239Cleerly, Inc.A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | 2026-12 |
| NCT03894423Stanford UniversityComprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery | 2026-12 |
| NCT07761728University of California, Los AngelesThe FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 1,104 studies in Coronary Artery Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the Coronary Plaque-Based Care arm will undergo CCTA with AI-enabled quantitative assessment of the morphology and composition of coronary atherosclerotic plaque and will receive medical and interventional management informed by CCTA findings and per discretion of the treating physician. All patients will receive a standardized assessment of clinical and risk factor status at baseline and 180 days.
Device: Cleerly Labs and Cleerly ISCHEMIA
Patients randomized to the Usual Care arm will be referred to their usual care providers for standard of care management post stress test findings, possibly including coronary angiography and/or revascularization per the treating provider's recommendation. All patients will receive a standardized assessment of clinical and risk factor status at baseline and 180 days.
Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.
The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 1\. Improved diagnostic certainty of CAD
Time frame: Through study completion- an average of 1 year
The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.
The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 2\. Reduction in LDL
Time frame: Through study completion- an average of 1 year
The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.
The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 3\. Freedom from ICA without a finding of obstructive CAD
Time frame: Through study completion- an average of 1 year
The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.
The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 4\. Freedom from PCI without finding of clinically significant stenosis
Time frame: Through study completion- an average of 1 year
The secondary objective of the study is to determine whether a management strategy improves patients' experience of chest pain, quality of life, and adherence to medication.
The secondary endpoints assess angina symptoms, medication adherence, and quality of life. 1\. Change in angina symptoms assessed using the Seattle Angina Questionnaire.
Time frame: Through study completion- an average of 1 year
The secondary objective of the study is to determine whether a management strategy improves patients' experience of chest pain, quality of life, and adherence to medication.
The secondary endpoints assess angina symptoms, medication adherence, and quality of life. 2\. Medication adherence assessed using the Voils DOSE-Nonadherence measure (Blalock, et al. 2019).
Time frame: Through study completion- an average of 1 year
The secondary objective of the study is to determine whether a management strategy improves patients' experience of chest pain, quality of life, and adherence to medication.
The secondary endpoints assess angina symptoms, medication adherence, and quality of life. 3\. Quality of life assessed using the 20-item Short Form Survey (SF-20).
Time frame: Through study completion- an average of 1 year
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 24 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cleerly, Inc.